Actively Recruiting
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Led by Maastricht Radiation Oncology · Updated on 2025-07-15
600
Participants Needed
3
Research Sites
286 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.
CONDITIONS
Official Title
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients selected to undergo primary surgical removal of lung cancer, including any type of lung resection such as wedge, segmental, lobectomy, or pneumonectomy
- Patients with suspected or confirmed lung cancer scheduled for bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy
You will not qualify if you...
- There are no exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Zuyderland Medical Center
Heerlen, Netherlands, 6419 PC
Actively Recruiting
2
Maastricht Radiation Oncology (Maastro)
Maastricht, Netherlands, 6229 ET
Not Yet Recruiting
3
MUMC+
Maastricht, Netherlands, 6229 HX
Actively Recruiting
Research Team
C
Chantal Overhof, BEc.
CONTACT
A
Ann Claessens
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here